Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
At four time points during neoadjuvant chemotherapy ± bevacizumab of receptor tyrosine-protein kinase erbB-2-negative breast cancers, we measured metabolites and inflammation-related markers in patient's serum.
|
31444972 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Addition of rNDV directly to iDCs culture induced DC maturation, as demonstrated by the increased expression of costimulatory and antigen-presenting molecules as well as the production of type I interferons (IFNs). rNDV infection of the HER-2 positive human breast cancer cell line (SKBR3) resulted in apoptotic cell death, release of proinflammatory cytokines, and danger-associated molecular pattern molecules (DAMPs) including high-mobility group protein B1 (HMGB1) and heat shock protein 70 (HSP70).
|
31584185 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
A retrospective series of 686 ER+/HER2- BC were reclassified using AJCC 2018, and in the group of 521 patients for which AJCC 2018 recommends molecular evaluation, we assessed the prognostic efficacy of a prognostic stage enriched by Ki67 (Ki67-PS), considering Ki67 <20% an alternative to recurrence score <11 provided by Oncotype DX.
|
31780778 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In addition, by using human epidermal growth factor receptor 2 (<i>HER2</i>) as a model, we quantified individual <i>HER2</i> mRNA molecules in clinical breast cancer FFPE tissue sections and demonstrated its potential to resolve FISH-equivocal cases.
|
31782306 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
HER2-targeting monoclonal antibodies resulted in longer survival of HER2<sup>+</sup> breast cancer.
|
31691197 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs <i>KIT</i>, <i>PDGFRA</i>, and <i>KDR</i> (4q12amp) may be similarly targetable.
|
31604903 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Arab women tended to be younger (P = 0.013), more disadvantaged (P < 0.001), were more likely to have symptomatic rather than screen-detected breast cancer (P < 0.001), had a higher rate of high grade (P = 0.021), HER2-positive (P = 0.025) breast cancer compared to Australian-born women or others.
|
31845467 |
2020 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Collectively these data define HER2 mutations as a therapeutic target in breast cancer and suggest that co-existence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib.
|
31806627 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
In 2013, HER2 results were evaluated using two sets of four different breast cancer specimens in five laboratories.
|
31424659 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
|
31841262 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Moreover, we found that there were 33 gene locus mutations of 8 genes including AKT1, APC, BRAF, CDKN2A, KRAS, PTEN, PIK3CA and TP53, but difference was not statistically significant (P > 0.05) when compared these gene mutations (except for PIK3CA) in each groups according to the histological classification of breast cancer and the ER/PR/HER2 classification.
|
30443844 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
|
31209793 |
2020 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HO-1 in HER2-expressing SKBR3 breast cancer cells resulted in reduced sensitivity to both pan-HER family kinase inhibitors sapatinib and lapatinib.
|
31705351 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Trastuzumab-mediated cardiotoxicity poses a significant challenge in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
|
31743871 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
HER2-positive primary breast cancer patients treated using NAC containing trastuzumab were enrolled between September 2006 and June 2017 at the Osaka Breast Clinic.
|
31574500 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
EpCAM (epithelial cellular adhesion molecule) and HER2 (human epidermal growth factor receptor 2) are two main circulating tumor cell (CTC) subsets in HER2+ breast cancer patients.
|
31583566 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this Review, we describe the current role of HER2-targeted therapies beyond breast cancer and also highlight the potential of novel HER2-targeted agents that are currently in clinical development.
|
31548601 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to evaluate the potential of HER-2/neu status as one of the important markers to classify the women suffering from breast cancer in upper Egypt and monitoring the responsiveness to different therapies.
|
31603098 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors.
|
31843452 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that the metastatic patterns in breast cancer strongly correlate with various breast cancer subtypes, mainly designated by ER, PR, and HER2.
|
31603096 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
All the above features makes our immunosensor a promising assay for the early diagnosis of HER2-dependent breast cancers in clinical diagnosis.
|
31790576 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy.
|
31037288 |
2020 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Notably, intermediate HER2 expression predicted poorer RFS in EBC patients aged ≥ 55 years (hazard ratio 1.95; p = 0.042) in multivariate Cox analysis but did not affect RFS in those aged < 55 years.
|
31811505 |
2020 |